Intrarectal Xyloglucan Administration Reduces Disease Severity in the Dextran Sodium Sulfate Model of Mouse Colitis
Edward A Ross,Madelyn H Miller,Allison Pacheco,Alicia R Willenberg,Justine T Tigno-Aranjuez,Kaitlyn E Crawford
DOI: https://doi.org/10.2147/CEG.S325945
2021-11-04
Clinical and Experimental Gastroenterology
Abstract:Edward A Ross, 1 Madelyn H Miller, 2 Allison Pacheco, 2 Alicia R Willenberg, 1 Justine T Tigno-Aranjuez, 2 Kaitlyn E Crawford 3 1 Department of Internal Medicine, College of Medicine, University of Central Florida, Orlando, FL, USA; 2 Immunity and Pathogenesis Division, Burnett School of Biomedical Sciences, University of Central Florida, Orlando, FL, USA; 3 Department of Materials Science and Engineering, College of Engineering and Computer Sciences, University of Central Florida, Orlando, FL, USA Correspondence: Edward A Ross Department of Medicine, College of Medicine, University of Central Florida, 6850 Lake Nona Blvd, Orlando, FL, 32827, USA Email Background: The pathophysiology of inflammatory bowel diseases remains poorly understood and treatment remains suboptimal for many patients. We hypothesize that the inflammatory milieu secondarily prolongs the injury and attenuates healing. We propose primary or adjuvant therapy with biocompatible adhesives to restore a barrier to protect submucosal structures, particularly stem cells. Methods: We used the well-described mouse dextran sodium sulfate (DSS) model of colitis resembling human ulcerative colitis to test the therapeutic efficacy of intrarectal administration of the tamarind plant-derived xyloglucan (TXG) polymer adhesive which underwent extensive analytic characterization. Mice in control, DSS-only, TXG-only, and DSS + TXG groups were studied for gross (weight, blood in stool, length of colon) and multiple histologic parameters. Results: Compared to DSS-only mice, TXG prevented the weight loss, occurrence of blood in the stool and colon shortening, with all those parameters not being statistically different from treatment naïve animals. Histologically, there was dramatic and highly statistically significant reduction in the total inflammatory index and protection from goblet cell loss, cellular infiltration, crypt abscess formation, epithelial erosion, granulation tissue, epithelial hyperplasia crypt irregularity and crypt loss. The TXG purity and characterization were established by nuclear magnetic resonance, infrared spectroscopy, differential scanning calorimetry, and texture analysis. Conclusion: The striking attenuation of disease severity by intrarectal TXG use warrants future investigations of natural bioadhesives with well-established high safety profiles, and which could potentially be derivatized to include therapeutically active moieties for local drug delivery. Keywords: ulcerative colitis, dextran sodium sulfate, DSS, xyloglucan, tamarind, inflammatory bowel disease In a mouse model resembling ulcerative colitis, intrarectal tamarind xyloglucan demonstrated profound protection for multiple whole animal and histologic parameters. These findings support the use of this plant-based polymer bioadhesive mucosal barrier as primary or adjuvant therapy for human disease. Despite advances in understanding the pathophysiology of inflammatory bowel diseases (IBD) and the development of new pharmaceuticals that target immunologic mechanisms, treatment remains suboptimal for many patients and do not specifically address protection of the colonic epithelial barrier We hypothesize that even with medications effectively targeting the underlying (eg, autoimmune and inflammatory) processes, healing is attenuated by the diseased milieu: 1 denudation of the epithelium; loss of the cellular and mucin barrier; infiltration by bacteria, toxins, cytokines and leukocytes; then submucosal inflammation and necrosis. We believe that the loss of stem cells in the crypts has a key role in thwarting recovery, as that process normally depends on precursor differentiation and proliferation. The goal of this study is to use a biocompatible adhesive as a protective barrier to chemical and cellular inflammatory compounds in the colon so as to shield submucosal structures, particularly stem cells. Rather than using inert coatings, a future approach is to administer bioadhesives that have innate anti-inflammatory activity or can be derivatized to deliver topical targeted pharmacologic treatment. The latter is an attractive goal since in situ medicinals may avoid adverse effects from systemic administration. Bioadhesives have a long history of medicinal use, and many are derived from plants rather than being prescription-based synthetic pharmacologic agents. Some natural compounds have been used as mechanical barrier coatings (for disorders of the eye, skin and stomach) and others are purported to have anti-inflammatory effects. 2–4 Many plant-derived moieties have a polymeric glucose backbone with side chains that determine tissue interactions. Their similarities to hum -Abstract Truncated-